Literature DB >> 9285527

The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha.

R H Lipsky1, D M Eckert, Y Tang, C F Ockenhouse.   

Abstract

The binding of oxidized low-density lipoprotein (Ox LDL) by monocyte-macrophages causes pleiotropic effects, including changes in gene expression, and is thought to represent an early event in atherogenesis. The integral membrane glycoprotein CD36 appears to play a physiological role in binding and uptake of Ox LDL by monocyte-macrophages, although the molecular events associated with CD36-Ox LDL interaction are unknown. To approach this issue, we used CD36 transfected Chinese hampster ovary (CHO) cells, exposed them to Ox LDL, and determined changes in the activity of the transcription factor NF-kappaB. We report here that Ox LDL enhanced DNA binding activity of nuclear extracts to an NF-kappaB sequence following activation of CD36-producing CHO cells with the proinflammatory cytokine tumor necrosis factor-alpha (TNF-alpha). This enhanced DNA binding activity was inhibited by coincubation of CD36 transfected cells with the human CD36-specific antibody OKM5. We also determined that activation of NF-kappaB DNA binding activity required an intact carboxyl-terminal cytoplasmic segment on CD36. Our results support the idea that human CD36 mediates signal transduction events in response to Ox LDL.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285527

Source DB:  PubMed          Journal:  Recept Signal Transduct        ISSN: 1087-8475


  8 in total

1.  The terminal six amino-acids of the carboxy cytoplasmic tail of CD36 contain a functional domain implicated in the binding and capture of oxidized low-density lipoprotein.

Authors:  Eric Malaud; Delphine Hourton; Louise Marie Giroux; Ewa Ninio; Robin Buckland; John L McGregor
Journal:  Biochem J       Date:  2002-06-01       Impact factor: 3.857

2.  CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD.

Authors:  Daryl M Okamura; Subramaniam Pennathur; Katie Pasichnyk; Jesús M López-Guisa; Sarah Collins; Maria Febbraio; Jay Heinecke; Allison A Eddy
Journal:  J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 10.121

3.  CD36-dependent signaling mediates fatty acid-induced gut release of secretin and cholecystokinin.

Authors:  Sinju Sundaresan; Rafiq Shahid; Terrence E Riehl; Rashmi Chandra; Fatiha Nassir; William F Stenson; Rodger A Liddle; Nada A Abumrad
Journal:  FASEB J       Date:  2012-12-11       Impact factor: 5.191

4.  CD36 protein is involved in store-operated calcium flux, phospholipase A2 activation, and production of prostaglandin E2.

Authors:  Ondrej Kuda; Christopher M Jenkins; James R Skinner; Sung Ho Moon; Xiong Su; Richard W Gross; Nada A Abumrad
Journal:  J Biol Chem       Date:  2011-03-31       Impact factor: 5.157

5.  Increased expression and activation of stress-activated protein kinases/c-Jun NH(2)-terminal protein kinases in atherosclerotic lesions coincide with p53.

Authors:  B Metzler; Y Hu; H Dietrich; Q Xu
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

6.  Targeting CD36-mediated inflammation reduces acute brain injury in transient, but not permanent, ischemic stroke.

Authors:  Eun-Hee Kim; Aaron T Tolhurst; Hazel H Szeto; Sung-Hee Cho
Journal:  CNS Neurosci Ther       Date:  2014-09-12       Impact factor: 5.243

7.  Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages.

Authors:  Mirko Lanuti; Emanuela Talamonti; Mauro Maccarrone; Valerio Chiurchiù
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

8.  RAGE deficiency does not affect non-alcoholic steatohepatitis and atherosclerosis in Western type diet-fed Ldlr-/- mice.

Authors:  Mitchell Bijnen; Nicky Beelen; Suzan Wetzels; José van de Gaar; Maria Vroomen; Erwin Wijnands; Jean L Scheijen; Marjo P H van de Waarenburg; Marion J Gijbels; Jack P Cleutjens; Erik A L Biessen; Coen D A Stehouwer; Casper G Schalkwijk; Kristiaan Wouters
Journal:  Sci Rep       Date:  2018-10-15       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.